公开(公告)号：US12215347B2

公开(公告)日：2025-02-04

申请号：US17381693

申请日：2021-07-21

Applicant: Allogene Therapeutics, Inc.

Inventor： Michael Thomas Bethune ,  Yi Zhang ,  Thomas John Van Blarcom ,  Siler Panowski ,  Barbra Johnson Sasu

IPC: C12N5/0783 ,  A61K39/00 ,  C07K14/725 ,  C12N15/86

Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

公开(公告)号：US20240425839A1

公开(公告)日：2024-12-26

申请号：US18821943

申请日：2024-08-30

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell GALINDO CASAS ,  Thomas John VAN BLARCOM

IPC: C12N9/64 ,  A61K31/7088 ,  A61K38/48 ,  A61K38/52 ,  A61K39/00 ,  C12N5/0783 ,  C12N9/90 ,  C12N11/18

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US12036243B2

公开(公告)日：2024-07-16

申请号：US17183689

申请日：2021-02-24

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui Lin ,  Siler Panowski ,  Cesar Adolfo Sommer ,  Thomas John Van Blarcom ,  Barbra Johnson Sasu ,  Arun Balakumaran

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/715 ,  C07K16/28 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/7151 ,  C07K16/2878 ,  C12N15/86

Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

公开(公告)号：US11673953B2

公开(公告)日：2023-06-13

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi Zhang ,  Thomas John Van Blarcom ,  Siler Panowski ,  Silvia K. Tacheva-Grigorova ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/70

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20220184124A1

公开(公告)日：2022-06-16

申请号：US17550311

申请日：2021-12-14

Applicant: Allogene Therapeutics, Inc.

Inventor： Lillian SEU ,  Melanie L. GEE ,  Michael A. BOWEN

IPC: A61K35/17 ,  C07K14/725 ,  C07K14/705

Abstract: Provided herein are methods, kits and reagents for analyzing attributes of engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of residual TCRαβ+ CAR T cells in allogeneic CAR T cell drug product and characterizing other important attributes of CAR T cell drug product.

公开(公告)号：US20220023346A1

公开(公告)日：2022-01-27

申请号：US17381693

申请日：2021-07-21

Applicant: Allogene Therapeutics, Inc.

Inventor： Michael Thomas BETHUNE ,  Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C12N15/86 ,  C07K14/725 ,  C12N5/0783

Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

公开(公告)号：US20200339944A1

公开(公告)日：2020-10-29

申请号：US16857394

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Diego A. VARGAS-INCHAUSTEGUI ,  Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C12N5/00 ,  C12N5/0783 ,  A61K35/17

Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).

公开(公告)号：US20200276238A1

公开(公告)日：2020-09-03

申请号：US16804545

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C12N15/67 ,  C07K16/30

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

公开(公告)号：US12221462B2

公开(公告)日：2025-02-11

申请号：US18484244

申请日：2023-10-10

Applicant: Allogene Therapeutics, Inc. ,  Les Laboratoires Servier

Inventor： Cyril Alkis Konto ,  Amina Zinai

IPC: A61K35/17 ,  A61K31/664 ,  A61K31/7076 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

公开(公告)号：US12163153B2

公开(公告)日：2024-12-10

申请号：US16857394

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Diego A. Vargas-Inchaustegui ,  Thomas Charles Pertel ,  Barbra Johnson Sasu

IPC: C12N5/00 ,  A61K35/17 ,  C12N5/0783

Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).